IRIS
CAROTENUTO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.477
EU - Europa 3.544
NA - Nord America 3.023
SA - Sud America 654
AF - Africa 121
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.834
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.882
SG - Singapore 2.353
RU - Federazione Russa 1.644
CN - Cina 1.106
IT - Italia 747
BR - Brasile 517
HK - Hong Kong 437
DE - Germania 378
VN - Vietnam 257
NL - Olanda 164
GB - Regno Unito 113
FI - Finlandia 103
IN - India 89
FR - Francia 80
CA - Canada 75
KR - Corea 69
IE - Irlanda 68
UA - Ucraina 62
AR - Argentina 52
ZA - Sudafrica 42
MX - Messico 38
CI - Costa d'Avorio 37
SE - Svezia 36
PL - Polonia 31
EC - Ecuador 27
ES - Italia 27
JP - Giappone 25
BD - Bangladesh 24
AT - Austria 22
LT - Lituania 19
IQ - Iraq 18
ID - Indonesia 17
TR - Turchia 17
VE - Venezuela 16
CO - Colombia 13
BE - Belgio 12
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
PK - Pakistan 8
CZ - Repubblica Ceca 7
SA - Arabia Saudita 7
TN - Tunisia 7
MA - Marocco 6
NP - Nepal 6
AU - Australia 5
EG - Egitto 5
IR - Iran 5
JO - Giordania 5
KE - Kenya 5
NI - Nicaragua 5
BO - Bolivia 4
DZ - Algeria 4
IL - Israele 4
MK - Macedonia 4
RS - Serbia 4
UY - Uruguay 4
BG - Bulgaria 3
CR - Costa Rica 3
CU - Cuba 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PE - Perù 3
PT - Portogallo 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
MD - Moldavia 2
PA - Panama 2
RE - Reunion 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BY - Bielorussia 1
CM - Camerun 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GY - Guiana 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
Totale 11.816
Salva come PNG Salva come JPEG
Città #
Singapore 1.138
Hong Kong 432
Moscow 427
Hefei 401
Ashburn 358
Beijing 313
Chandler 309
Santa Clara 217
Naples 164
Amsterdam 128
Los Angeles 128
Ho Chi Minh City 91
Munich 86
Millbury 77
Seoul 69
Dallas 62
Des Moines 55
New York 55
São Paulo 53
Boston 50
Napoli 50
Buffalo 49
Hanoi 49
Redondo Beach 49
Milan 40
Nanjing 38
Princeton 37
Seattle 37
Lawrence 36
Helsinki 34
Denver 33
Krefeld 33
The Dalles 32
Frankfurt am Main 29
Norwalk 28
Stockholm 26
Montreal 25
Dong Ket 24
Falkenstein 24
Warsaw 24
London 23
Turku 23
Chicago 22
Tokyo 21
Johannesburg 20
Rome 20
Council Bluffs 18
Mexico City 18
Toronto 18
Nuremberg 17
Orem 17
Pune 17
Boardman 16
Brooklyn 16
Dublin 16
Lappeenranta 16
Tianjin 16
Wilmington 16
Houston 15
Ottawa 15
Rio de Janeiro 15
Rottweil 15
Atlanta 14
Chennai 14
Düsseldorf 14
Poplar 14
Cava De' Tirreni 12
Phoenix 12
Ankara 11
Belo Horizonte 11
Curitiba 11
Haiphong 11
Manchester 11
Mumbai 11
Bari 10
Brasília 10
Catania 9
Formia 9
Nanchang 9
Portsmouth 9
Quito 9
Shanghai 9
Brussels 8
Da Nang 8
Jiaxing 8
Porto Alegre 8
Shenyang 8
Vienna 8
Washington 8
Campinas 7
Cape Town 7
Redwood City 7
Sant'arpino 7
Turin 7
Baghdad 6
Biên Hòa 6
Bollate 6
Charlotte 6
Guayaquil 6
Hebei 6
Totale 6.047
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 246
Uric acid: a potential biomarker of multiple sclerosis and of its disability 177
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 136
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 135
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 134
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 130
The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study 129
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 128
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 128
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 127
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 127
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 124
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 124
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 124
The use of medical-grade cannabis in patients non-responders to Nabiximols 121
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis 121
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 121
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 119
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 118
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 117
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 116
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 115
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 114
Inhibition of oligodendrocyte differentiation by immunoglobulin purified from serum of multiple sclerosis patients during relapse 114
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 114
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy 113
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 112
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 112
Retinal vascular density in multiple sclerosis: a one year follow up 112
A real-world study of alemtuzumab in a cohort of Italian patients 111
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 110
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 110
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 109
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 109
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 109
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 109
Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition 108
Exploring the relation between reserve and fatigue in multiple sclerosis 107
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 106
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 106
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 106
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 105
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 105
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 105
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis 104
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 103
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 103
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 101
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 101
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 100
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 99
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. 98
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 97
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 97
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 97
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 96
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 96
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 96
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 95
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 95
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 94
Anatomical and functional retinal changes in multiple sclerosis 94
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 93
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 93
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 92
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 92
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 91
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 91
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 90
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 90
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 90
Can people with multiple sclerosis actually understand what they read in the Internet age? 89
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 89
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 89
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 89
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 89
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis 88
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 88
Correction to: Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 87
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 87
Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data 87
Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis 86
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 86
Integration of the expanded disability status scale with ambulation, visual and cognitive tests 85
Dysphagia assessment in patients with multiple sclerosis - an additional piece to disability burden 84
A longitudinal real-life comparison study of natalizumab and fingolimod 83
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 82
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 81
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications 80
Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia 78
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 78
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 76
Epilepsy in ring 14 chromosome syndrome 75
The Framingham cardiovascular risk score in multiple sclerosis 75
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 74
Association between CD20+ T lymphocytes and neuropsychological findings in multiple sclerosis 73
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 71
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis 69
Retinal and choriocapillary vascular changes in early stages of multiple sclerosis: A prospective study 68
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 67
Totale 10.264
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 11 9 5 24 11 20 33
2021/2022467 8 1 4 6 11 36 8 17 58 34 105 179
2022/20231.000 81 87 20 43 87 125 152 53 152 132 45 23
2023/2024678 32 96 84 56 41 85 17 71 21 17 101 57
2024/20254.075 182 179 32 72 132 251 437 282 248 435 1.425 400
2025/20265.040 843 746 894 913 1.487 157 0 0 0 0 0 0
Totale 12.188